Brief: Revive Therapeutics Enters into Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize Novel Long COVID Rapid Test
06/11/2023 14:08
Nov 6 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS ENTERS INTO WORLDWIDE EXCLUSIVE
AGREEMENT
WITH LAWSON HEALTH RESEARCH INSTITUTE TO DEVELOP AND
COMMERCIALIZE A NOVEL LONG COVID RAPID TEST
* REVIVE THERAPEUTICS LTD: EVALUATING DIAGNOSTIC COMPANION
WITH
BUCILLAMINE FOR LONG COVID
Source text for Eikon: ID:nGNX1PhR0J
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure